首页> 美国卫生研究院文献>PLoS Clinical Trials >Impact of CD68/(CD3+CD20) Ratio at the Invasive Front of Primary Tumors on Distant Metastasis Development in Breast Cancer
【2h】

Impact of CD68/(CD3+CD20) Ratio at the Invasive Front of Primary Tumors on Distant Metastasis Development in Breast Cancer

机译:CD68 /(CD3 + CD20)比在原发性肿瘤浸润前部对乳腺癌远处转移发展的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumors are infiltrated by macrophages, T and B-lymphocytes, which may favor tumor development by promoting angiogenesis, growth and invasion. The aim of this study was to investigate the clinical relevance of the relative amount of macrophages (CD68+), T-cells (CD3+) and B-cells (CD20+) at the invasive front of breast carcinomas, and the expression of matrix metalloproteases (MMPs) and their inhibitors (TIMPs) either at the invasive front or at the tumor center. We performed an immunohistochemical study counting CD3, CD20 and CD68 positive cells at the invasive front, in 102 breast carcinomas. Also, tissue sections were stained with MMP-2, -9, -11, -14 and TIMP-2 antibodies, and immunoreactivity location, percentage of reactive area and intensity were determined at the invasive front and at the tumor center. The results showed that an increased CD68 count and CD68/(CD3+CD20) ratio were directly associated with both MMP-11 and TIMP-2 expression by mononuclear inflammatory cells at the tumor center (p = 0.041 and p = 0.025 for CD68 count and p = 0.001 and p = 0.045 for ratio, respectively for MMP-11 and TIMP-2). In addition, a high CD68/(CD3+CD20) ratio (>0.05) was directly associated with a higher probability of shortened relapse-free survival. Multivariate analysis revealed that CD68/(CD3+CD20) ratio was an independent factor associated with distant relapse-free survival (RR: 2.54, CI: (1.23–5.24), p<0.01). Therefore, CD68/(CD3+CD20) ratio at the invasive front could be used as an important prognostic marker.
机译:肿瘤被巨噬细胞,T和B淋巴细胞浸润,这可能通过促进血管生成,生长和侵袭而促进肿瘤的发展。这项研究的目的是研究巨噬细胞(CD68 + ),T细胞(CD3 + )和B细胞(CD20 < sup> + )在乳腺癌的浸润前部,基质金属蛋白酶(MMPs)及其抑制剂(TIMPs)在浸润前部或肿瘤中心的表达。我们进行了一项免疫组织化学研究,对102例乳腺癌的浸润前期CD3,CD20和CD68阳性细胞进行了计数。同样,组织切片用MMP-2,-9,-11,-14和TIMP-2抗体染色,并在浸润前线和肿瘤中心确定免疫反应性位置,反应面积百分比和强度。结果表明,增加的CD68计数和CD68 /(CD3 + CD20)比值与肿瘤中心单核炎性细胞的MMP-11和TIMP-2表达直接相关(CD68计数分别为p = 0.041和p = 0.025)。 MMP-11和TIMP-2的比率分别为p = 0.001和p = 0.045)。此外,高CD68 /(CD3 + CD20)比(> 0.05)与缩短无复发生存期的较高可能性直接相关。多变量分析显示,CD68 /(CD3 + CD20)比率是与远距离无复发生存相关的独立因素(RR:2.54,CI:(1.23-5.24),p <0.01)。因此,浸润前部的CD68 /(CD3 + CD20)比可作为重要的预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号